ArticleMolecular biology reports2026
miR-26b-modified human umbilical cord mesenchymal stem cells exhibit enhanced anti-fibrotic efficacy in a mouse model of hepatic fibrosis.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveConventional human umbilical cord mesenchymal stem cells (HUCMSCs) show insufficient liver homing and limited therapeutic efficacy against hepatic fibrosis. This work aimed to construct miR-26b-overexpressing HUCMSCs (Ad-26b-HUCMSCs) and explore their anti-fibrotic capacity and underlying mechanisms.
methodsAdenovirus was applied to achieve miR-26b overexpression in HUCMSCs. CCK-8, Transwell and flow cytometry assessed cell viability, migration and apoptosis in vitro. A CCl₄-induced mouse hepatic fibrosis model was established, with four animal groups receiving sham treatment, PBS, Ad-HUCMSCs or Ad-26b-HUCMSCs via tail vein injection. Liver function, serum cytokines, liver histopathology, cell homing and hepatic marker expression were measured 28 days post-transplantation.
resultsmiR-26b modification significantly enhanced HUCMSC viability, migratory ability and liver engraftment without increasing apoptosis. Ad-26b-HUCMSCs markedly lowered serum ALT, AST, IL-1β, IL-6 and TGF-β, relieved hepatic collagen deposition, suppressed α-SMA and TNF-α, and elevated AFP, ALB and CK18 expression in injured liver compared with unmodified HUCMSCs.
conclusionsmiR-26b overexpression improves the survival, liver-targeted migration and hepatic marker expression of HUCMSCs. Ad-26b-HUCMSCs exert potent anti-fibrotic effects, offering an optimized stem cell therapeutic strategy for hepatic fibrosis.
Indexed as
Identifiers
42573841What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.